Umbilical cord serum eyedrops
PreclinicalSmall molecule
Umbilical cord serum eyedrops is one of 23 small molecule programs targeting Dry Eye Syndrome. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
22 competitors in Dry Eye Syndrome
#DrugCompanyPhaseTrials
1Neoral
NovartisApproved
Aldactone
PfizerApproved
Revia
TevaApproved
Estrace
Novo NordiskApproved
Decadron
AAspen Global Incorporated
Approved
Isopto Carpine
AAdvanz Pharma
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Xeljanz
PPrism Pharmaceuticals
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Dry Eye Syndrome1 trial
Comparison of Autologous Serum and Umbilical Cord Serum Eyedrops for Dry Eye Syndrome
Completed·—·N/A·NCT00442273
Unspecified1 trial
Umbilical Cord Serum Eye Drops
Completed·—·N/A·NCT01016158
Sources
References
- [1]
- [2]
- [3]
- [4]
Details